Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised
Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.
How this was made
The 30-second read
Why it matters
Traders should focus on the raised guidance details, the magnitude and nature of reimbursement adjustments, and whether Medicaid attrition and commercial cost overages are likely to persist into Q4 given the wide EBITDA range.
Market read
Raised Q4 2026 EBITDA guidance alongside broad outperformance, but the call also flags Medicaid attrition risk and a wide Q4 EBITDA range that can drive expectation dispersion.
What to watch
Medicaid-related membership attrition is tracking toward the high end of expectations, and the RAF cohort mix plus conservative planning (zero HQOF contribution) could cap upside even with cost management levers.
Background
Astrana Health’s Q2 2026 earnings call covered reimbursement adjustments (ACO REACH), medical cost trends, Medicaid attrition, and a transition of Medi-Cal risk arrangements plus RAF improvement outlook.
Ticker impact
Astrana Health raised Q4 2026 EBITDA guidance while citing broad-based outperformance and a $15M ACO REACH revenue reduction tied to CMS billing adjustments.
Near-term volatility likely as traders weigh raised guidance against the wide Q4 EBITDA range and Medicaid membership attrition.
The article provides specific guidance direction (raised) plus quantified items ($15M revenue reduction, wide EBITDA range) and operational drivers (RAF transition, cost trend, Medicaid attrition), which can move expectations and positioning.
Market effects
Highlights ongoing Medicare/Medicaid risk-adjustment and coding/RAF dynamics that can influence managed-care peers’ margin expectations.
Medi-Cal (California Medicaid) RAF transition and disenrollment dynamics may be a read-through for other Medicaid-heavy operators in the state.
Limited, primarily US managed-care operational and reimbursement mechanics.
Counterpoint
The $15M ACO REACH revenue reduction is described as immaterial net EBITDA impact, so the raised guidance may dominate despite the wide Q4 range.
Key entities
- companyAstrana Health Inc
NASDAQ-listed managed care provider reporting Q2 2026 results and raised Q4 2026 EBITDA guidance, with reimbursement and membership dynamics driving the outlook.
- executiveBrandon Sim
CEO who discussed RAF transition, cost trend management, and guidance interpretation (midpoint focus).
- executiveChandan Basho
CFO/COO who clarified the $15M ACO REACH revenue reduction and its net EBITDA impact.
